NCT05701488 - SIRT With Tremelimumab and Durvalumab for Resectable HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

Resectable Hepatocellular CarcinomaHepatocellular CarcinomaHepatocellular Cancer

Interventions

DRUG

Durvalumab

Intravenous infusion

DRUG

Tremelimumab

Intravenous infusion

DEVICE

SIRT

SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.

Trial Locations (3)

NOT_YET_RECRUITING

Cedars-Sinai Medical Center, Los Angeles

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston